Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat alzheimer’s disease
Palabras clave :
Alzheimer’s disease
Multitarget therapy
Histone deacetylase
Phosphodiesterase
Memory
Fecha de publicación :
2019
Editorial :
Frontiers Media SA
Nota:
This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Cita:
Cuadrado-Tejedor, M. (Mar); Pérez-González, M. (Marta); García-Muñoz, C. (Cristina); et al. "Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat alzheimer’s disease". Frontiers in Aging Neuroscience. 11 (149), 2019,
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.